Work

1412TiP Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.1726

Authors: P.A. Jänne, Y-L. Wu, T. Kato, B. Besse, S. Peters, D. Nguyen, D. Berg, J. Lin, Z. Feng, T. Mok

Institutions: Dana-Farber Cancer Institute, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Kanagawa Cancer Center, Institut Gustave Roussy, Centre Hospitalier Universitaire Vaudois, Takeda Oncology (United States), Chinese University of Hong Kong

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3089052367

FWCI: 0.867

Cites:

Cited by: 7

Related to: 10